CARsgen Announces Investigational CAR-T Therapy CT053, after PRIME eligibility by EMA, Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma
CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of